New drug UCB9741 tested for safety in healthy people

NCT ID NCT06315335

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested the safety and tolerability of a single dose of UCB9741 in 40 healthy adults, including both Caucasian and Japanese participants. Half received the drug and half a placebo, with neither participants nor researchers knowing who got what. The study focused on side effects and how the drug moves through the body, not on treating any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

UCB9741

What could go wrong

This is an early Phase 1 study in healthy volunteers, so it cannot show whether the drug works for any disease. The main goal is safety, not treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Up0118 10001

    Glendale, California, 91206, United States